← 返回

使用抗 G4S 连接肽抗体进行磁性 CAR-T 细胞纯化

英文原题:Magnetic CAR T cell purification using an anti-G4S linker antibody.

查看英文原题

Magnetic CAR T cell purification using an anti-G4S linker antibody.

PubMed 2024/04/02(内容时间) J Immunol Methods Q4 · IF 1.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

靶向嵌合抗原受体(CAR)的T细胞已成功用于治疗多种血液系统恶性肿瘤,但转导率偏低常影响疗效,因此需要优化CAR-T 细胞产品。

我们报告一种适用范围广的富集方案:先用抗甘氨酸4-丝氨酸(G4S)连接肽抗体标记CAR-T 细胞,再进行磁珠活化细胞分选(MACS)。该方案适用范围广,因为G4S肽是绝大多数CAR的组成部分,负责连接VH和VL识别结构域。

我们使用分别靶向CEA和Her2的经典第二代CAR证明该方案可行,可通过一步操作获得高度纯化的CAR-T 细胞产品,且不损害细胞活性。该方案也适用于双特异性CAR(串联CAR)。除CD39外,分选后T细胞活化/耗竭标志物均未上调。纯化后的CAR-T 细胞仍保留功能,包括抗原特异性细胞因子分泌、细胞毒性、增殖能力,以及重复刺激后清除对应肿瘤细胞的能力。

总体而言,这种一步法CAR-T 细胞纯化方案扩展了临床前研究工具,也为临床CAR-T 细胞制备提供了新方法。

展开英文摘要原文

Chimeric antigen receptor (CAR) redirected T cells are successfully employed in the combat against several hematological malignancies, however, are often compromised by low transduction rates making refinement of the CAR T cell products necessary.

Here, we report a broadly applicable enrichment protocol relying on marking CAR T cells with an anti-glycine 4 -serine (G4S) linker antibody followed by magnetic activated cell sorting (MACS). The protocol is broadly applicable since the G4S peptide is an integral part of the vast majority of CARs as it links the VH and VL recognition domains.

We demonstrate the feasibility by using the canonical second generation CARs specific for CEA and Her2, respectively, obtaining highly purified CAR T cell products in a one-step procedure without impairing cell viability. The protocol is also applicable to a dual specific CAR (tandem CAR). Except for CD39, T cell activation/exhaustion markers were not upregulated after separation.

Purified CAR T cells retained their functionality with respect to antigen-specific cytokine secretion, cytotoxicity, and the capacity to proliferate and eliminate cognate tumor cells upon repetitive stimulation. Collectively, the one-step protocol for purifying CAR T cells extends the toolbox for preclinical research and specifically for clinical CAR T cell manufacturing.

论文信息

作者
Harrer DC、Li SS、Kaljanac M、Bezler V、Barden M、Pan H、Herr W、Abken H
单位
Department of Internal Medicine III - Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany; Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, and Chair Genetic Immunotherapy, University Regensburg, Germany. Electronic address: dennis.harrer@ukr.de.Germany
文献类型
非美国政府资助研究
期刊
Journal of immunological methods2024 May
原文标识
PubMed 38574803 · DOI 10.1016/j.jim.2024.113667